ArticleJournal of virology2026
ViralMap: predicting features in viral proteins from primary sequence.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern viral vaccines are designed to elicit an immune response against viral proteins that mediate infection, making those proteins important targets for characterization and engineering. To improve vaccine efficacy, the proteins often require changes to specific residues or domains to enhance immunogenicity and induce a protective response. These engineering strategies vary significantly across viruses, making comprehensive and accurate protein sequence annotation a crucial step for guiding vaccine design. The growing risk of novel pathogen emergence and initiatives such as the CEPI 100 Days Mission to rapidly counter "Disease X" threats heighten the need for tools that can convert viral protein sequences from newly characterized genomes or emerging variants into the annotation profiles required for antigen engineering. To address this, we developed ViralMap, a multi-label annotation model tailored for eukaryotic viral proteins. By leveraging ESM-2 language model representations, ViralMap simultaneously predicts 10 distinct annotation classes spanning domain topology and localization, post-translational modifications, and structural features directly from primary sequences. The model achieves a residue-level precision-recall area under the curve (PR-AUC) of 0.75 or greater for 7 of the 10 classes, with performance competitive with established tools across the eight benchmarked classes. Case studies on complex glycoproteins from SARS-CoV-2, HIV-1, Nipah virus, and Lassa virus demonstrate the model's ability to predict detailed residue-level annotation profiles, including for proteins from viral families not seen during training. By providing a unified, sequence-based framework for multi-label annotation, ViralMap offers a practical bridge from raw viral protein sequences to the annotation profiles required for antigen engineering.IMPORTANCEThe rapid characterization of viral proteins is critical for developing vaccines against emerging pathogens. When a new strain or virus is identified, researchers need to efficiently identify key features of these proteins to guide vaccine design. Currently, obtaining such features requires running multiple computational tools, which are generally not specialized for viruses that affect humans. ViralMap is a deep learning model that addresses this gap by predicting ten functionally relevant protein annotations simultaneously from sequence alone. Trained specifically on eukaryotic viral proteins, ViralMap aims to support the early stages of vaccine engineering for pandemic preparedness efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.